Arvinas is a clinical-stage biotechnology company. Co.'s investigational clinical stage programs include: ARV-471, which is an investigational orally bioavailable PROTAC protein degrader designed for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; bavdegalutamide (ARV-110), which is an investigational orally bioavailable PROTAC protein degrader designed for the treatment of men with metastatic castration-resistant prostate cancer, or mCRPC; and ARV-766, which is an investigational orally bioavailable PROTAC protein degrader designed to target AR with a different profile than bavdegalutamide, as a potential treatment for men with mCRPC. We show 23 historical shares outstanding datapoints in our ARVN shares outstanding history coverage, used to compute ARVN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ARVN market cap history over the course of time is important for investors
interested in comparing ARVN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ARVN versus a peer is one thing; comparing
ARVN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ARVN can fluctuate over the course of history.
With this page we aim to empower investors researching ARVN by allowing them to research the ARVN market cap history. |
Free ARVN Email Alerts:
Video: The Importance of Market Cap
